Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain training app takes on long COVID disability

NCT ID NCT07530757

First seen Apr 28, 2026 · Last updated Jun 23, 2026 · Updated 12 times

Summary

This study tests a supervised online program called SuperCAP to see if it can improve thinking and daily functioning in people with long COVID. One hundred adults with post-COVID cognitive difficulties will either use the program or receive standard education. The goal is to reduce disability and improve quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST COVID CONDITION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fundació Lluita contra les Infeccions - Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, 08916, Spain

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Supervised Computerized Active Program (SuperCAP) - an online program with cognitive exercises, fatigue management, and education

What this could lead to

If it works, this could offer a practical, non-drug way to ease brain fog and fatigue in long COVID, helping people get back to daily activities.

What could go wrong

This is a small, early-stage trial with only 100 participants. The program may not work for everyone, and results might not apply to all long COVID patients.

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.